Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties
Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties
Solution allows for the transfer of digital data quickly and safely to new mobile devices BRIDGEWATER, N.J., Nov. 18, 2021 (GLOBE NEWSWIRE) — Anticipating a